Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

NCT03020628 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: NBP607-QIV
BIOLOGICAL: NBP607-TIV

Sponsor

SK Chemicals Co., Ltd.